{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:13:29Z","timestamp":1791987209516,"version":"4.4.0"},"reference-count":89,"publisher":"MDPI AG","issue":"23","license":[{"start":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T00:00:00Z","timestamp":1732924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The advent of advanced molecular diagnostic techniques has revealed plenty of information about signaling pathways and gene regulation in cancer, as well as new inputs for the classification of cancer subtypes, diagnosis, prognosis, and prediction of response to therapy. However, in most cases we do not have single biomarkers yet and, therefore, the final diagnosis is often rendered by the combination of multiple results by means of complex algorithms, eventually leading to an increase in their costs. The problem of the costs of such tests is particularly relevant in the case of thyroid cancer (TC), because of the observed increase in the number of patients affected by thyroid nodules (TN)s, in what is considered a global pandemic. High-income countries can afford the cost of the advanced molecular tests for such a multitude of TNs, since they are covered by private insurances. People living in upper-middle, lower-middle, and especially in low-income countries, where the costs for these advanced molecular tests are supported by general taxation and out-of-pocket payments, are exposed as a personal financial burden. Immunohistochemistry in cancer management represents an extremely cost-effective method in different clinical scenarios. In the preoperative recognition of TC, the use of such method, based on Galectin-3 and others protein markers, such as HMBE1, proved to be effective in diagnosing TC in TNs indeterminate at conventional cytology (Bethesda classification III or IV), with an extremely low cost. Moreover, Galectin-3 fulfills one of the major criteria of an ideal marker, being involved in the thyroid cell transformation. Despite this evidence, Galectin-3 ThyroTest is not considered and not even mentioned in many reviews, focused on the appropriate identification of TC, as well as in studies where the cost-effectiveness of the different approaches is comparatively evaluated. The aim of this review is to emphasize the value of the Galectin-3 based immunohistochemistry as a cheap and \u201cgood enough\u201d method in the preoperative diagnosis of TC especially in, but not limited to, low-middle income countries.<\/jats:p>","DOI":"10.3390\/jcm13237290","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T11:48:56Z","timestamp":1733226536000},"page":"7290","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Unappreciated Value of a Cheap, \u2018Good Enough\u2019 Method of Detecting Thyroid Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1492-5365","authenticated-orcid":false,"given":"Salvatore","family":"Sciacchitano","sequence":"first","affiliation":[{"name":"Department of Life Sciences, Health and Health Professions, Link Campus University, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Rugge","sequence":"additional","affiliation":[{"name":"Department of Medicine DIMED Pathology and Cytopathology Unit, University of Padova, 35122 Padova, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7820-5127","authenticated-orcid":false,"given":"Armando","family":"Bartolazzi","sequence":"additional","affiliation":[{"name":"Pathology Research Laboratory, St Andrea University Hospital, 00189 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1200\/JCO.2006.09.6081","article-title":"Cost of cancer care: Issues and implications","volume":"25","author":"Meropol","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/S1470-2045(11)70141-3","article-title":"Delivering affordable cancer care in high-income countries","volume":"12","author":"Sullivan","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.7326\/M24-0375","article-title":"The Annual Cost of Cancer Screening in the United States","volume":"177","author":"Halpern","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mathers, C.D., and Loncar, D. (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med., 3.","DOI":"10.1371\/journal.pmed.0030442"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S1470-2045(13)70547-3","article-title":"Evidence-informed frameworks for cost-effective cancer care and prevention in low, middle, and high-income countries","volume":"15","author":"Chalkidou","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMp1604412","article-title":"World-wide thyroid-cancer epidemic? The increasing impact of overdiagnosis","volume":"375","author":"Vaccarella","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1089\/thy.2015.0116","article-title":"The impact of diagnostic changes on the rise in thyroid cancer incidence: A population-based study in selected high-resource countries","volume":"25","author":"Vaccarella","year":"2015","journal-title":"Thyroid"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.surg.2015.06.049","article-title":"Cost disparity between health care systems\u2013it\u2019s not the surgeons: A cost analysis of thyroid cancer care between the United States and France","volume":"159","author":"Finnerty","year":"2016","journal-title":"Surgery"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.ejso.2015.01.019","article-title":"Initial attributable cost and economic burden of clinically relevant differentiated thyroid cancer: A health care service provider perspective","volume":"41","author":"Lang","year":"2015","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/1055-9965.EPI-13-0242","article-title":"The clinical and economic burden of a sustained increase in thyroid cancer incidence","volume":"22","author":"Schechter","year":"2013","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1093\/jnci\/djab192","article-title":"Annual report to the nation on the status of cancer, part 2: Patient economic burden associated with cancer care","volume":"113","author":"Yabroff","year":"2021","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1210\/jc.2017-02754","article-title":"Gene expression classifier vs targeted next-generation sequencing in the management of indeterminate thyroid nodules","volume":"103","author":"Livhits","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1001\/jamaoncol.2020.5935","article-title":"Effectiveness of molecular testing techniques for diagnosis of indeterminate thyroid nodules: A randomized clinical trial","volume":"7","author":"Livhits","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamasurg.2018.1153","article-title":"Performance of a genomic sequencing classifier for the preoperative diagnosis of cytologically indeterminate thyroid nodules","volume":"153","author":"Patel","year":"2018","journal-title":"JAMA Surg."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1001\/jamaoncol.2018.4616","article-title":"Performance of a multigene genomic classifier in thyroid nodules with indeterminate cytology: A prospective blinded multicenter study","volume":"5","author":"Steward","year":"2019","journal-title":"JAMA Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1089\/thy.2019.0539","article-title":"The role of the ThyroSeq v3 molecular test in the surgical management of thyroid nodules in the Canadian public healthcare setting","volume":"30","author":"Chen","year":"2020","journal-title":"Thyroid"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/cncy.21612","article-title":"Molecular cytopathology for thyroid nodules: A review of methodology and test performance","volume":"124","author":"Nishino","year":"2016","journal-title":"Cancer Cytopathol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Mu, C., Ming, X., Tian, Y., Liu, Y., Yao, M., Ni, Y., Liu, Y., and Li, Z. (2022). Mapping global epidemiology of thyroid nodules among general population: A systematic review and meta-analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1029926"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Uppal, N., Collins, R., and James, B. (2023). Thyroid nodules: Global, economic, and personal burdens. Front. Endocrinol., 14.","DOI":"10.3389\/fendo.2023.1113977"},{"key":"ref_21","first-page":"238","article-title":"Financial toxicity in thyroid cancer survivors","volume":"30","author":"Bogdanovski","year":"2023","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S2213-8587(22)00101-2","article-title":"Diagnosis of thyroid nodules","volume":"10","author":"Alexander","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1089\/thy.2015.0098","article-title":"Risk factors for decreased quality of life in thyroid cancer survivors: Initial findings from the north American thyroid cancer survivorship study","volume":"25","author":"James","year":"2015","journal-title":"Thyroid"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/S2213-8587(20)30115-7","article-title":"Global trends in thyroid cancer incidence and the impact of overdiagnosis","volume":"8","author":"Li","year":"2020","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1001\/jamaoncol.2022.7826","article-title":"Estimates and Projections of the Global Economic Cost of 29 Cancers in 204 Countries and Territories From 2020 to 2050","volume":"9","author":"Chen","year":"2023","journal-title":"JAMA Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/0002-9343(92)90163-6","article-title":"Thyroid cancer in thyroid nodules: Finding a needle in the haystack","volume":"93","author":"Mazzaferri","year":"1992","journal-title":"Am. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"US Preventive Services Task Force, Bibbins-Domingo, K., Grossman, D.C., Curry, S.J., Barry, M.J., Davidson, K.W., Doubeni, C.A., Epling, J.W., Kemper, A.R., and Krist, A.H. (2017). US Preventive Services Task Force. Screening for thyroid cancer: US Preventive Services Task Force Recommendation Statement. JAMA, 317, 1882\u20131887.","DOI":"10.1001\/jama.2017.4011"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.2018.0898","article-title":"The Diagnosis and Management of Thyroid Nodules","volume":"319","author":"Durante","year":"2018","journal-title":"A Review. JAMA"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid Cancer A Review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"ref_32","first-page":"T301","article-title":"Molecular approaches to thyroid cancer diagnosis","volume":"21","author":"Hsiao","year":"2014","journal-title":"Endocr. Relat. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.5858\/2000-124-1185-TCEOI","article-title":"The Cost-Effectiveness of Immunohistochemistry","volume":"124","author":"Raab","year":"2000","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtho.2018.12.005","article-title":"Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer","volume":"14","author":"Yatabe","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.2353\/ajpath.2010.090353","article-title":"Diagnostic utility of galectin-3 in thyroid cancer","volume":"176","author":"Chiu","year":"2010","journal-title":"Am. J. Pathol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1210\/jc.2011-1469","article-title":"Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: A prospective analysis of 1056 FNA samples","volume":"96","author":"Nikiforov","year":"2011","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the Multi-Gene ThyroSeq Next-Generation Sequencing Assay on Cancer Diagnosis in Thyroid Nodules with Atypia of Undetermined Significance\/Follicular Lesion of Undetermined Significance Cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1203208","article-title":"Preoperative diagnosis of benign thyroid nodules with indeterminate cytology","volume":"367","author":"Alexander","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","article-title":"Progress in molecular-based management of differentiated thyroid cancer","volume":"381","author":"Xing","year":"2013","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E761","DOI":"10.1210\/jc.2012-3762","article-title":"Does addition of BRAF V600E mutation testing modify sensitivity or specificity of the Afirma Gene Expression Classifier in cytologically indeterminate thyroid nodules?","volume":"98","author":"Kloos","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"S69","DOI":"10.21037\/gs.2019.10.26","article-title":"European perspective on the use of molecular tests in the diagnosis and therapy of thyroid neoplasms","volume":"9","author":"Krajewska","year":"2020","journal-title":"Gland. Surg."},{"key":"ref_42","unstructured":"(2024, October 29). Evidence Review for Molecular Testing: Thyroid Cancer: Assessment and Management: Evidence Review F, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK589403\/."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1001\/jama.2024.5995","article-title":"A Review of Thyroid Cancer","volume":"331","author":"Sciacchitano","year":"2024","journal-title":"JAMA"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1001\/jamainternmed.2013.232","article-title":"IImpact of Providing Fee Data on Laboratory Test Ordering: A Controlled Clinical Trial","volume":"173","author":"Feldman","year":"2013","journal-title":"JAMA Intern. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Sciacchitano, S., Lavra, L., Morgante, A., Ulivieri, A., Magi, F., De Francesco, G.P., Bellotti, C., Salehi, L.B., and Ricci, A. (2018). Galectin-3 one molecule for an alphabet of disease. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020379"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/glycob\/3.4.297","article-title":"The family of metazoan metal-independent beta-galactoside-binding lectins: Structure, function and molecular evolution","volume":"4","author":"Hirabayashi","year":"1993","journal-title":"Glycobiology"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.bbagen.2005.12.020","article-title":"Galectin-3: An open-ended story","volume":"1760","author":"Dumic","year":"2006","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1023\/B:GLYC.0000014082.99675.2f","article-title":"Extracellular functions of Gal-3","volume":"19","author":"Ochieng","year":"2004","journal-title":"Glycoconj. J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/glycob\/12.5.329","article-title":"Shuttling of Gal-3 between the nucleus and cytoplasm","volume":"12","author":"Davidson","year":"2002","journal-title":"Glycobiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/B:GLYC.0000014080.95829.52","article-title":"Regulation of cellular homeostasis by galectins","volume":"19","author":"Hsu","year":"2004","journal-title":"Glycoconj. J."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1006\/excr.1995.1331","article-title":"Intranuclear distribution of galectin-3 in mouse 3T3 fibroblasts: Comparative analyses by immunofluorescence and immunoelectron microscopy","volume":"220","author":"Hubert","year":"1995","journal-title":"Exp. Cell Res."},{"key":"ref_52","first-page":"5272","article-title":"Gal-3: A novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family","volume":"57","author":"Akahani","year":"1997","journal-title":"Cancer Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10495-005-0801-y","article-title":"On the role of Gal-3 in cancer apoptosis","volume":"10","author":"Nakahara","year":"2005","journal-title":"Apoptosis"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jmb.2013.12.004","article-title":"Galectin-3 interactions with glycosphingolipids","volume":"426","author":"Collins","year":"2014","journal-title":"J. Mol. Biol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hauselmann, I., and Borsig, L. (2014). Altered tumor-cell glycosylation promotes metastasis. Front. Oncol., 4.","DOI":"10.3389\/fonc.2014.00028"},{"key":"ref_56","first-page":"3015","article-title":"Gal-3 is a presurgical marker of human thyroid carcinoma","volume":"58","author":"Orlandi","year":"1998","journal-title":"Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO;2-1","article-title":"Expression of Gal-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms","volume":"85","author":"Inohara","year":"1999","journal-title":"Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1016\/S0140-6736(00)04817-0","article-title":"Thyroid Cancer Study Group. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions","volume":"357","author":"Bartolazzi","year":"2001","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(08)70132-3","article-title":"Galectin-3- expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: A prospective multicentre study","volume":"9","author":"Bartolazzi","year":"2008","journal-title":"Lancet Oncol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/PAI.0b013e31821ee9bb","article-title":"Methodology and technical requirements of the galectin-3 test for the preoperative characterization of thyroid nodules","volume":"20","author":"Bartolazzi","year":"2012","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/modpathol.3800321","article-title":"Galectin-3 and HBME-1 expression in well-differentiated thyroid tumors with follicular architecture of uncertain malignant potential","volume":"18","author":"Papotti","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/modpathol.3800235","article-title":"Galectin-3, fibronectin-1, CITED-1, HBME1 and cytokeratin-19 immunohistochemistry is useful for the differential diagnosis of thyroid tumors","volume":"18","author":"Prasad","year":"2005","journal-title":"Mod. Pathol."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Crescenzi, A., and Baloch, Z. (2023). Immunohistochemistry in the pathologic diagnosis and management of thyroid neoplasms. Front. Endocrinol, 14.","DOI":"10.3389\/fendo.2023.1198099"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12020-015-0774-8","article-title":"Combined clinical and ultrasound follow-up assists in malignancy detection in Galectin-3 negative Thy-3 thyroid nodules","volume":"54","author":"Sciacchitano","year":"2016","journal-title":"Endocrine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Bartolazzi, A., Sciacchitano, S., and D\u2019Alessandria, C. (2018). Galectin-3: The Impact on the Clinical Management of Patients with Thyroid Nodules and Future Perspectives. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19020445"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0304-3835(03)00056-9","article-title":"Malignant transformation of thyroid follicular cells by galectin-3","volume":"195","author":"Takenaka","year":"2003","journal-title":"Cancer Lett."},{"key":"ref_68","first-page":"787","article-title":"Galectin-3 maintains the transformed phenotype of thyroid papillary carcinoma cells","volume":"18","author":"Yoshii","year":"2001","journal-title":"Int. J. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1128\/MCB.00959-05","article-title":"Repression of the antiapoptotic molecule galectin-3 by homeodomain-interacting protein kinase 2-activated p53 is required for p53-induced apoptosis","volume":"26","author":"Cecchinelli","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/path.2510","article-title":"Gal-3 is stimulated by gain-of-function p53 mutations and modulates chemoresistance in anaplastic thyroid carcinomas","volume":"218","author":"Lavra","year":"2009","journal-title":"J. Pathol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Lavra, L., Rinaldo, C., Ulivieri, A., Luciani, E., Fidanza, P., Giacomelli, L., Bellotti, C., Ricci, A., Trovato, M., and Soddu, S. (2011). The loss of the p53 activator HIPK2 is responsible for galectin-3 overexpression in well differentiated thyroid carcinomas. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0020665"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"ii11","DOI":"10.1136\/bmjqs-2012-001616","article-title":"How much diagnostic safety can we afford, and how should we decide? A health economics perspective","volume":"22","author":"McDonald","year":"2013","journal-title":"BMJ Qual. Saf."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/CCO.0000000000001012","article-title":"Pathology and new insights in thyroid neoplasms in the 2022 WHO classification","volume":"36","author":"Lebrun","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"ref_74","first-page":"e66186","article-title":"Advances in the Diagnosis and Treatment of Follicular Thyroid Carcinoma: A Comprehensive Review","volume":"16","author":"Gopalan","year":"2024","journal-title":"Cureus"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s11154-023-09842-0","article-title":"Molecular testing for thyroid nodules: Where are we now?","volume":"25","author":"Ferraz","year":"2024","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3322\/caac.21833","article-title":"Cancer screening with multicancer detection tests: A translational science review","volume":"74","author":"Rubinstein","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.suc.2024.02.004","article-title":"The Role of Molecular Markers in Thyroid Cancer Diagnostics and Treatment","volume":"104","author":"Sada","year":"2024","journal-title":"Surg. Clin. N. Am."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1210\/jc.2011-3048","article-title":"Cost impact of molecular testing for indeterminate thyroid nodule fine-needle aspiration biopsies","volume":"97","author":"Yip","year":"2012","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s40463-022-00604-7","article-title":"Cost-effectiveness analysis of molecular testing for cytologically indeterminate thyroid nodules","volume":"51","author":"Dharampal","year":"2022","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1210\/jc.2014-1219","article-title":"Cost-effectiveness of molecular testing for thyroid nodules with atypia of undetermined significance cytology","volume":"99","author":"Lee","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jval.2012.06.017","article-title":"Cost-effectiveness of using a molecular diagnostic test to improve preoperative diagnosis of thyroid cancer","volume":"15","author":"Najafzadeh","year":"2012","journal-title":"Value Health"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Tessler, I., Leshno, M., Feinmesser, G., Alon, E.E., and Avior, G. (2023). Is There a Role for Molecular Testing for Low-Risk Differentiated Thyroid Cancer? A Cost-Effectiveness Analysis. Cancers, 15.","DOI":"10.3390\/cancers15030786"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1089\/thy.2018.0779","article-title":"Molecular Testing Versus Diagnostic Lobectomy in Bethesda III\/IV Thyroid Nodules: A Cost-Effectiveness Analysis","volume":"29","author":"Nicholson","year":"2019","journal-title":"Thyroid"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"49421","DOI":"10.18632\/oncotarget.17220","article-title":"Comparative analysis of diagnostic performance, feasibility and cost of different test-methods for thyroid nodules with indeterminate cytology","volume":"8","author":"Sciacchitano","year":"2017","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer Statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"ref_87","first-page":"14","article-title":"Cheap and easy cancer diagnosis?","volume":"4","author":"Carlson","year":"2007","journal-title":"Biotechnol. Healthc."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1007\/s40267-020-00766-2","article-title":"Current burden on healthcare systems in low- and middle-income countries: Recommendations for emergency care of COVID-19","volume":"36","author":"Hamid","year":"2020","journal-title":"Drugs Ther. Perspect."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Eisenstein, M. (2023). Putting low-cost diagnostics to the test. Nature, ahead-of-print.","DOI":"10.1038\/d41586-023-03576-4"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7290\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:43:20Z","timestamp":1760114600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/23\/7290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,30]]},"references-count":89,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["jcm13237290"],"URL":"https:\/\/doi.org\/10.3390\/jcm13237290","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,30]]}}}